Anxiety Disorders

September, 2013 | Vol: 11 Issue: 9

In this issue

Learning Objective


Antipsychotics and Anticonvulsants for Anxiety Disorders

Anxiety Disorders - The Carlat Psychiatry Report (TCPR)

We know how frequently our patients complain of anxiety. Anxiety disorders are common, chronic conditions. They also increase the risk for mood and substance disorders, and complaints of anxiety are found in a wide range of other psychiatric and medical conditions, as well.

Expert Q&A

Anxiety Disorders in DSM-5 and Beyond

Dr Daniel Pine, chief of the section on Development and Affective Neuroscience at the NIMH and chair of the DSM-5 Work Group on Child and Adolescent Psychiatric Disorders discusses anxiety disorders in the current and future state of anxiety disorder research and practice.

Research Update

Is Dose Reduction the Ideal Strategy after First Episode of Psychosis?

What’s the optimal treatment for a first episode of psychosis? Few would argue against antipsychotic treatment, but what happens when the patient achieves remission?

News of Note

Fetzima Approved for Depression

In July 2013, the FDA approved the SNRI Fetzima (levomilnacipran) for major depressive disorder (MDD) in adults (Forest Laboratories, Inc). The efficacy of Fetzima at doses 40 mg to 120 mg once daily was established in three, eight-week, randomized, double-blind, placebo-controlled studies in adults diagnosed MDD.